Group 1 - The core viewpoint of the news is that the stock price of Chongqing Shanwaishan Blood Purification Technology Co., Ltd. has shown fluctuations, with a recent decline of 2.01% and a current trading price of 15.61 yuan per share, while the company has experienced a year-to-date stock price increase of 4.28% [1][2] - As of October 31, 2025, the company reported a revenue of 584 million yuan, representing a year-on-year growth of 39.79%, and a net profit attributable to shareholders of 104 million yuan, reflecting a year-on-year increase of 68.68% [2] - The company specializes in the research, production, and sales of blood purification equipment, with its main business revenue composition being 66.12% from blood purification equipment, 23.89% from blood purification consumables, 8.31% from medical services, and 1.68% from other sources [2] Group 2 - The company has distributed a total of 104 million yuan in dividends since its A-share listing [3] - As of September 30, 2025, the top ten circulating shareholders include new shareholder Penghua Medical Technology Stock A, holding 5.182 million shares, and BoShi Medical Care Mixed A, holding 3.257 million shares, with the latter's shareholding remaining unchanged from the previous period [3]

12月31日，山外山跌0.80%，成交额4207.31万元。两融数据显示，当日山外山获融资买入额620.50万 元，融资偿还715.94万元，融资净买入-95.44万元。截至12月31日，山外山融资融券余额合计9517.01万 元。 融资方面，山外山当日融资买入620.50万元。当前融资余额9486.18万元，占流通市值的1.98%，融资余 额超过近一年60%分位水平，处于较高位。 机构持仓方面，截止2025年9月30日，山外山十大流通股东中，鹏华医药科技股票A（001230）位居第 四大流通股东，持股518.20万股，为新进股东。博时医疗保健混合A（050026）位居第六大流通股东， 持股325.70万股，持股数量较上期不变。 责任编辑：小浪快报 资料显示，重庆山外山血液净化技术股份有限公司位于重庆市两江新区慈济路1号，成立日期2001年3月 26日，上市日期2022年12月26日，公司主营业务涉及血液净化设备的研发、生产和销售。主营业务收入 构成为：血液净化设备66.12%，血液净化耗材23.89%，医疗服务8.31%，其他1.68%。 截至10月31日，山外山股东户数1.12万，较上期增加8.86%；人 ...

12月1日，山外山盘中下跌2.02%，截至14:29，报15.00元/股，成交5400.13万元，换手率1.53%，总市值 47.94亿元。 资金流向方面，主力资金净流出180.60万元，特大单买入0.00元，占比0.00%，卖出233.02万元，占比 4.32%；大单买入568.04万元，占比10.52%，卖出515.61万元，占比9.55%。 分红方面，山外山A股上市后累计派现1.04亿元。 机构持仓方面，截止2025年9月30日，山外山十大流通股东中，鹏华医药科技股票A（001230）位居第 四大流通股东，持股518.20万股，为新进股东。博时医疗保健混合A（050026）位居第六大流通股东， 持股325.70万股，持股数量较上期不变。 责任编辑：小浪快报 资料显示，重庆山外山血液净化技术股份有限公司位于重庆市两江新区慈济路1号，成立日期2001年3月 26日，上市日期2022年12月26日，公司主营业务涉及血液净化设备的研发、生产和销售。主营业务收入 构成为：血液净化设备66.12%，血液净化耗材23.89%，医疗服务8.31%，其他1.68%。 山外山所属申万行业为：医药生物-医疗器械-医疗设备。所 ...

Meeting Overview - The shareholders' meeting was held on November 14, 2025, at the conference room on the 8th floor, No. 1 Ciji Road, Liangjiang New Area, Chongqing [2] - The total share capital of the company as of the registration date was 321,315,646 shares, with 1,666,341 shares in the repurchase account not entitled to vote, resulting in a total of 319,649,305 shares eligible for voting [2] Voting and Resolutions - The meeting was convened by the board of directors, with the chairman attending online due to official duties, and a director was elected to preside over the meeting [3] - The voting method combined on-site and online voting, complying with relevant laws and regulations [3] - All proposed resolutions were passed, including the reappointment of the accounting firm for 2025 and amendments to the company's articles of association [4][5][6] Attendance and Legal Compliance - All current directors and supervisors attended the meeting, along with the board secretary and senior management [4] - The meeting's procedures were verified by Guangdong Huashang (Chongqing) Law Firm, confirming compliance with the Company Law and other regulations [6] Documentation - The resolutions from the shareholders' meeting were documented and signed by the attending directors and the recording person, along with a legal opinion from the witnessing law firm [7]

Core Points - The company will hold a performance briefing for the third quarter of 2025 on November 11, 2025, from 09:00 to 10:00 [2][4] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [3][4] - Investors can submit questions from November 4 to November 10, 2025, and the company will address common concerns during the briefing [2][4] Meeting Details - The meeting will be attended by key personnel including the Chairman and General Manager, Mr. Gao Guangyong, and the Financial Director and Secretary of the Board, Ms. Yu Shangling [4] - Investors can participate online through the Shanghai Stock Exchange Roadshow Center website [4][6] - After the meeting, the main content and details will be available for review on the same website [6][7]

Core Viewpoint - The company, Chongqing Shanwaishan Blood Purification Technology Co., Ltd., has shown significant growth in revenue and net profit for the first nine months of 2025, indicating strong operational performance in the medical device sector [2]. Financial Performance - For the period from January to September 2025, the company achieved a revenue of 584 million yuan, representing a year-on-year growth of 39.79% [2]. - The net profit attributable to the parent company reached 104 million yuan, marking a year-on-year increase of 68.68% [2]. Stock Performance - As of October 30, the company's stock price decreased by 2.05%, trading at 16.26 yuan per share, with a total market capitalization of 5.225 billion yuan [1]. - Year-to-date, the stock price has increased by 47.02%, with a 11.91% rise over the last five trading days [1]. Shareholder Information - As of September 30, the number of shareholders increased to 10,300, a rise of 26.20% compared to the previous period [2]. - The average number of circulating shares per shareholder decreased by 20.76% to 22,805 shares [2]. Dividend Distribution - Since its A-share listing, the company has distributed a total of 104 million yuan in dividends [3]. Institutional Holdings - As of September 30, 2025, among the top ten circulating shareholders, Penghua Medical Technology Stock A is the fourth largest with 5.182 million shares, marking a new entry [3]. - Bosera Healthcare Mixed A remains the sixth largest shareholder, holding 3.257 million shares, unchanged from the previous period [3].

Core Insights - On October 10, the stock of Chongqing Shanwaishan Blood Purification Technology Co., Ltd. increased by 3.66%, with a trading volume of 134 million yuan [1] - As of October 10, the company had a total margin balance of 113 million yuan, with a net margin purchase of 1.69 million yuan on that day [1][2] - For the first half of 2025, the company reported a revenue of 357 million yuan, representing a year-on-year growth of 28.72%, and a net profit of 55 million yuan, up 20.28% year-on-year [2] Financing and Margin Data - On October 10, the financing buy amount was 10.93 million yuan, with a current financing balance of 113 million yuan, accounting for 3.08% of the circulating market value [1] - The financing balance is above the 80th percentile level over the past year, indicating a high level of financing activity [1] - The company had no short selling activity on October 10, with a short selling balance of 0.00 yuan, which is below the 30th percentile level over the past year, indicating low short selling interest [1] Shareholder and Dividend Information - As of June 30, the number of shareholders increased by 2.67% to 8,150, while the average circulating shares per person decreased by 2.60% to 28,779 shares [2] - Since its A-share listing, the company has distributed a total of 104 million yuan in dividends [3] - Among the top ten circulating shareholders, Bosera Healthcare Mixed A (050026) is the fifth largest shareholder, increasing its holdings by 746,300 shares [3]

Company Overview - The company, Chongqing Shanwaishan Blood Purification Technology Co., Ltd., was established on March 26, 2001, and went public on December 26, 2022. It is located at No. 1 Ciji Road, Liangjiang New Area, Chongqing [2]. - The main business involves the research, production, and sales of blood purification equipment, with revenue composition as follows: blood purification equipment 66.12%, blood purification consumables 23.89%, medical services 8.31%, and others 1.68% [2]. Stock Performance - As of September 24, the stock price increased by 2.16% to 14.66 CNY per share, with a total market capitalization of 4.71 billion CNY [1]. - Year-to-date, the stock price has risen by 32.55%, but it has seen a decline of 2.66% over the last five trading days and 5.84% over the last 20 days [2]. Financial Performance - For the first half of 2025, the company achieved a revenue of 357 million CNY, representing a year-on-year growth of 28.72%. The net profit attributable to the parent company was 55.04 million CNY, up by 20.28% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 104 million CNY in dividends [3]. Shareholder Information - As of June 30, 2025, the number of shareholders increased by 2.67% to 8,150, while the average circulating shares per person decreased by 2.60% to 28,779 shares [2]. - Among the top ten circulating shareholders, Bosera Healthcare Mixed A (050026) is the fifth largest, holding 3.26 million shares, an increase of 746,300 shares from the previous period [3].

来源：新浪证券-红岸工作室 大健康：拟通过集中竞价交易或大宗交易的方式减持不超过12,852,625股，减持比例不超过公司总 股本4.00%，减持期间为自减持计划公告之日起15个交易日后的3个月内（2025年10月14日至2026 年1月11日）。大健康属于已在中国证券投资基金业协会完成备案的创业投资基金，截至公司首次 公开发行上市日，其投资期限在60个月以上，减持股份总数不受比例限制。 任应祥：拟通过集中竞价交易的方式减持不超过249,539股，减持比例不超过公司总股本0.08%， 减持期间同样为2025年10月14日至2026年1月11日。减持价格将按照减持实施时的市场价格确定， 且在2025年10月14日至2025年12月25日期间减持价格不低于因公司除权除息事项调整后的发行价 14.23元/股。 在减持期间，大健康和任应祥将根据市场情况、公司股价等因素决定是否实施本次减持计划，本次减持 计划的实施存在减持时间、减持数量、减持价格等不确定性。不过，本次减持计划不会导致上市公司控 制权发生变更，且符合相关法律法规以及规范性文件的规定。减持计划实施期间，相关股东将严格按规 定及监管要求实施减持，并及时履行信 ...

广东华商（重庆）律师事务所 广东华商（重庆）律师事务所 广东华商（重庆）律师事务所 关于重庆山外山血液净化技术股份有限公司 关于重庆山外山血液净化技术股份有限公司 法律意见书 二〇二五年九月四日 （一）本次股东大会召集人的资格 重庆山外山血液净化技术股份有限公司（以下简称"公司"）2025 年第二次临 时股东大会定于 2025 年 9 月 4 日于两江新区慈济路 1 号 8 楼会议室召开，广东华商 （重庆）律师事务所（以下简称"本所"）接受公司的委托，指派孟显慧律师、代星 宇律师（以下简称"本所律师"）通过现场参会方式对本次股东大会进行见证并出具本见 证意见。 本所律师依据本法律意见书出具前已经发生或者存在的事实和《中华人民共和国公司 法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上 市公司股东会规则》（以下简称《股东会规则》）及其他现行有效的法律、法规及规范性 文件规定及《重庆山外山血液净化技术股份有限公司章程》（以下简称《公司章程》） 的有关规定出具本法律意见书。 为出具本法律意见书，本所律师已经对公司提供的与本次股东大会有关的法律文件及 其他文件、资料予以了核查、验证。在 ...